Clinical Trials Logo

Recurrent Renal Cell Cancer clinical trials

View clinical trials related to Recurrent Renal Cell Cancer.

Filter by:

NCT ID: NCT00182702 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer

Start date: July 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well ixabepilone works in treating patients with metastatic, recurrent, or unresectable kidney cancer. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing

NCT ID: NCT00112840 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer

Start date: May 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial is studying the side effects and best dose of CCI-779 and bevacizumab and to see how well they work in treating patients with metastatic or unresectable kidney cancer. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of kidney cancer by blocking blood flow to the tumor. Giving CCI-779 together with bevacizumab may kill more tumor cells.

NCT ID: NCT00112476 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors

Start date: March 2005
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of temsirolimus when given together with bryostatin 1 in treating patients with unresectable or metastatic solid tumors. Drugs used in chemotherapy, such as temsirolimus and bryostatin 1, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

NCT ID: NCT00101114 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer

Start date: September 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving sorafenib with interferon alfa works in treating patients with metastatic or unresectable kidney cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer. Sorafenib may help interferon alfa work better by making tumor cells more sensitive to the drug

NCT ID: NCT00091182 Completed - Clinical trials for Recurrent Rectal Cancer

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

Start date: October 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00089362 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors

Start date: July 2004
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as alvespimycin hydrochloride, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00078858 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant

Start date: September 2003
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies whether stopping cyclosporine before mycophenolate mofetil is better at reducing the risk of life-threatening graft-versus-host disease (GVHD) than the previous approach where mycophenolate mofetil was stopped before cyclosporine. The other reason this study is being done because at the present time there are no curative therapies known outside of stem cell transplantation for these types of cancer. Because of age or underlying health status, patients may have a higher likelihood of experiencing harm from a conventional blood stem cell transplant. This study tests whether this new blood stem cell transplant method can be made safer by changing the order and length of time that immune suppressing drugs are given after transplant.

NCT ID: NCT00060307 Completed - Clinical trials for Stage IV Renal Cell Cancer

Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

Start date: May 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well erlotinib works in treating patients with locally advanced or metastatic papillary renal cell (kidney) cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth

NCT ID: NCT00059813 Completed - Clinical trials for Stage IV Renal Cell Cancer

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

Start date: August 2003
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of combining oblimersen with interferon alfa in treating patients who have metastatic renal cell (kidney) cancer. Interferon alfa may interfere with the growth of tumor cells. Oblimersen may increase the effectiveness of interferon alfa by making tumor cells more sensitive to the drug.

NCT ID: NCT00032188 Completed - Clinical trials for Stage IV Renal Cell Cancer

Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer

Start date: January 2002
Phase: Phase 2
Study type: Interventional

Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining bryostatin 1 with interleukin-2 may cause a stronger immune response and kill more tumor cells. Randomized phase II trial to study the effectiveness of combining interleukin-2 and bryostatin 1 in treating patients who have advanced kidney cancer